Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.

Abstract

RATIONALE:

Multiple primary malignant tumors are rare and challenging to diagnose. Diffuse malignant peritoneal mesothelioma (DMPM) originate from the peritoneum, which lacks specific clinical manifestations and is difficult to diagnose, with a short survival about 10 to 13 months for inoperable ones. This is the first report of metachronous double primary malignant tumors in nasopharyngeal carcinoma and DMPM accompanied with paraneoplastic syndromes.

PATIENT CONCERNS:

A 61-year-old man presented with abdominal discomfort with a history of nasopharyngeal carcinoma 5 years ago.

DIAGNOSES:

The diagnosis of DMPM was finally confirmed by laparoscopic mesenteric biopsies. Paraneoplastic syndromes including increased platelets were present when diagnosis, followed by increased neutrophils after disease progression.

INTERVENTIONS:

Due to intolerable for surgery, he was treated with pemetrexed combined with nivolumab, intraperitoneal infusion of nivolumab, radiotherapy, anlotinib and maintenance treatment of nivolumab.

OUTCOMES:

Progression-free survival in first line is 12 months, overall survival is 23 months.

LESSONS:

This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes.

• Authors: Liang-Ke Tang, Zhi-Ke Li, Ya-Lang Xiang, Dai-Yuan Ma, Guo-Bo Du
• Journal: Medicine (Medicine (Baltimore)) Vol. 102 Issue 30 Pg. e34349 (Jul 28 2023) ISSN: 1536-5964 [Electronic] United States
• PMID: 37505161 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Nivolumab

Topics

• Male
• Humans
• Middle Aged
• Peritoneum (pathology)
• Nivolumab (therapeutic use)
• Mesothelioma (complications, drug therapy)
• Nasopharyngeal Carcinoma
• Mesothelioma, Malignant
• Peritoneal Neoplasms (therapy, drug therapy)
• Paraneoplastic Syndromes (etiology)
• Nasopharyngeal Neoplasms (complications, drug therapy)